NEW YORK, Dec. 31, 2014 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company") (Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014.
Click here to learn about the case: http://docs.wongesq.com/SLXP-Info-Request-Form-545. There is no cost or obligation to you.
The complaint alleges that the Company made false and misleading statements and/or concealed material information regarding deteriorating demand and increasing inventory levels for Xifaxan and other Salix drugs.
On November 6, 2014 and November 7, 2014, Salix disclosed that its Chief Financial Officer had resigned, its wholesaler inventory levels were three times greater than previously reported, and that its previously-issued guidance for full-year 2014 revenues would not be met and would be drastically reduced.
If you suffered a loss in Salix you have until January 6, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/SLXP-Info-Request-Form-545.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.